Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Regulatory News (OXB)

Share Price Information for Oxford Biomedica (OXB)

Share Price is delayed by 15 minutes
Get Live Data
630.00    30.00 (5.00%)
Bid:
626.00
Ask:
634.00
Spread: 8.00 (1.278%)
Market Cap: £762.36m
OXB Live PriceLast checked at - London Stock Exchange

Intraday Oxford Biomedica Share Chart

Block listing Return

1 Jul 2020 15:44

RNS Number : 7603R
Oxford Biomedica PLC
01 July 2020
 

For Immediate Release

01 July 2020

 

OXFORD BIOMEDICA PLC

 

BLOCK LISTING RETURN

 

Name of applicant:

OXFORD BIOMEDICA PLC

Name of scheme:

2015 Employee Share Option Scheme

Period of return:

From:

01Jan 2020

To:

30 June 2020

Balance of unallotted securities under scheme(s) from previous return:

10,856

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

200,000

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

37,842

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

173,014

 

 

Name of applicant:

OXFORD BIOMEDICA PLC

Name of scheme:

2015 Long Term Incentive Plan

Period of return:

From:

01Jan 2020

To:

30 June 2020

Balance of unallotted securities under scheme(s) from previous return:

270,875

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

NIL

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

59,136

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

211,739

 

 

 

Name of applicant:

OXFORD BIOMEDICA PLC

Name of scheme:

2015 Deferred Bonus Plan

Period of return:

From:

01Jan 2020

To:

30 June 2020

Balance of unallotted securities under scheme(s) from previous return:

102,346

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

NIL

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

16,702

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

85,644

 

 

 

Name of applicant:

OXFORD BIOMEDICA PLC

Name of scheme:

Sharesave Scheme

Period of return:

From:

01Jan 2020

To:

30 June 2020

Balance of unallotted securities under scheme(s) from previous return:

159,044

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

200,000

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

66,864

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

292,180

 

 

 

Name of contact:

Natalie Walter

Telephone number of contact:

01865 783000

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BLRRBMITMTIMBTM
Date   Source Headline
30th Jun 201710:38 amRNSRefinancing of Debt Facility
23rd Jun 201710:12 amRNSDirector Dealings / Market Share Purchase
14th Jun 20173:00 pmRNSFindings from Phase II JULIET Study
7th Jun 20177:00 amRNSOXB notes FDA Advisory Committee to review CTL019
2nd Jun 20177:00 amRNSOXB to Present at Jefferies Healthcare Conference
1st Jun 201712:22 pmRNSTotal Voting Rights
24th May 20171:55 pmRNSDirector/PDMR Shareholding
23rd May 20172:03 pmRNSResult of AGM
4th May 20178:46 amRNSTotal Voting Rights
28th Apr 20177:00 amRNSAnnual Report and Accounts & AGM Notification
24th Apr 201710:17 amRNSDirector/PDMR Shareholding
4th Apr 20177:00 amRNSHolding(s) in Company
3rd Apr 20179:11 amRNSTotal Voting Rights
31st Mar 20177:15 amRNSHardman: Delivering commercial gene-therapy vector
30th Mar 20177:02 amRNSBLA filing for CTL019
27th Mar 201710:44 amRNSPublication in the Journal Nature Communications
23rd Mar 20171:47 pmRNSDirector Dealings
22nd Mar 20177:00 amRNSHolding(s) in Company
16th Mar 20177:00 amRNSPRELIMINARY RESULTS FOR THE YEAR ENDED 31 DEC 2016
10th Mar 20177:00 amRNSNotice of Preliminary Results
1st Mar 201710:24 amRNSTotal Voting Rights
28th Feb 20177:00 amRNSAppointment of New Chief Financial Officer
24th Feb 20179:36 amRNSDirector Dealings
24th Feb 20177:00 amRNSResults of TroVax® in Advanced Colorectal Cancer
1st Feb 201710:09 amRNSTotal Voting Rights
25th Jan 20179:02 amRNSDirector/PDMR Shareholding
24th Jan 20174:34 pmRNSDirector Dealings / Market Share Purchase
24th Jan 20179:31 amRNSDirector/PDMR Shareholding
23rd Jan 20179:57 amRNSDirector/PDMR Shareholding
3rd Jan 20179:30 amRNSBlock Listing Return
3rd Jan 20179:28 amRNSTotal Voting Rights
20th Dec 20168:57 amRNSDirector/PDMR Shareholding
12th Dec 201610:52 amRNSBlock listing application
6th Dec 20169:15 amRNSDirector/PDMR Shareholding
5th Dec 201610:25 amRNSFindings Reported by Novartis on CTL-019 at ASH
5th Dec 20169:43 amRNSDirector/PDMR Shareholding
1st Dec 20169:27 amRNSTotal Voting Rights
29th Nov 20167:00 amRNSStrategic Alliance with Orchard Therapeutics
28th Nov 201610:06 amRNSDirector/PDMR Shareholding
8th Nov 20166:28 pmRNSGrant of options (Replacement)
8th Nov 20166:13 pmRNSGrant of options
1st Nov 201610:21 amRNSTotal Voting Rights
25th Oct 20164:40 pmRNSDirector/PDMR Shareholding
10th Oct 20167:21 amRNSPublication of RetinoStat® (OXB-201) Phase I study
6th Oct 20169:24 amRNSHolding(s) in Company
5th Oct 201610:17 amRNSHolding(s) in Company
4th Oct 201611:57 amRNSHolding(s) in Company
4th Oct 20168:16 amRNSAdmission to Trading and Total Voting Rights
29th Sep 201612:27 pmRNSResult of General Meeting and Directors Dealing
26th Sep 201611:00 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.